Welcome to our dedicated page for Waldencast plc news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast plc stock.
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform built around the Obagi Medical and Milk Makeup brands. Its news flow centers on segment performance, brand initiatives, and platform-level strategic decisions, providing investors and observers with regular insight into how the company executes its brand-led strategy.
Company updates frequently include quarterly and half-year financial results, furnished to the U.S. Securities and Exchange Commission on Form 6-K and summarized in detailed press releases. These communications break out net revenue, adjusted gross profit, and adjusted EBITDA for Waldencast as a whole and for the Obagi Medical and Milk Makeup segments, highlighting trends across channels and geographies as described by the company.
News related to Obagi Medical often covers product and portfolio developments, clinical data, and expansion into aesthetics. Examples include announcements about FDA approval of Obagi-branded hyaluronic acid injectable products, new clinical data on Obagi hyaluronic acid injectables and scalp serum at professional dermatology meetings, and the acquisition of Novaestiq Corp. and U.S. rights to the Saypha injectable line. These items illustrate how Waldencast presents Obagi Medical’s role at the intersection of skincare and medical aesthetics.
Updates about Milk Makeup focus on brand performance in prestige beauty and digital channels, including references to U.S. retail sales trends, expansion into retailers such as Ulta Beauty and Amazon Premium Beauty, and the impact of specific product launches as described in the company’s quarterly commentary.
At the corporate level, Waldencast’s news also addresses strategic reviews and financing actions, such as the announced review of strategic alternatives by the Board of Directors, the sale of the “Obagi” trademark in Japan, and new credit agreements. Readers of the WALD news page can expect a mix of earnings updates, brand-specific developments, clinical and regulatory milestones, and capital structure announcements directly sourced from company press releases and related SEC filings.
Waldencast (NASDAQ: WALD), a global beauty platform, reported mixed H1 2025 results with notable developments. Obagi Medical achieved double-digit growth in core strategic channels and completed the Novaestiq acquisition, doubling its U.S. addressable market. Milk Makeup delivered high-20s growth in U.S. retail sales in Q2, driven by Ulta Beauty expansion and Amazon Premium Beauty launch.
The company revised its FY 2025 guidance to low to mid-single digit revenue growth with adjusted EBITDA margins in the low to mid-teens. Waldencast announced a strategic review to maximize shareholder value and postponed H1 2025 earnings release for additional analysis. Key challenges included international market softness, retailer destocking, and out-of-stock issues, though improving.
Waldencast (NASDAQ: WALD) has announced the acquisition of Novaestiq Corp. and U.S. rights to the Saypha® hyaluronic acid injectable gel line. The strategic move expands Obagi Medical's portfolio beyond skincare into the dermal filler market, effectively doubling its addressable market to $4.2 billion by 2029.
The transaction terms include cash payment, ongoing royalties, and potential issuance of Waldencast class A shares representing approximately 7% of fully diluted shares, contingent on FDA approval and revenue milestones of $100 million and $200 million. The Saypha® line, currently pending FDA approval, is globally recognized and manufactured in Austria with distribution in over 80 countries.
This acquisition positions Obagi Medical to become a leading dermatological mega brand by combining medical-grade skincare with aesthetic treatments, supported by extensive clinical studies particularly focused on diverse skin types.
Waldencast (NASDAQ: WALD) has scheduled its First Quarter Fiscal 2025 earnings conference call and webcast for May 14, 2025, at 8:30am ET. The company will release its Q1 FY2025 financial results on May 13, 2025 after U.S. market close. Investors and analysts can participate by dialing (877) 704-4453, or (201) 389-0920 for international callers. A slide presentation will accompany the webcast, accessible at ir.waldencast.com, with a replay available on the website for 90 days.
Obagi Medical, a subsidiary of Waldencast plc (NASDAQ: WALD) and the fastest-growing professional skincare brand in the U.S. in 2024, has launched its new Retinol + PHA Refining Night Cream. The $135 product combines Entrapped Retinol with Polyhydroxy Acid (PHA) Gluconolactone in a slow-release formula.
The clinical study demonstrated significant results after four weeks:
- 29% increase in skin smoothness
- 10% improvement in skin tone evenness
- 90% of users reported visibly smoother skin texture
- 90% observed reduced blemish appearance
The formula includes eight additional ingredients including Sodium Hyaluronate, Vitamin E, Squalane, and Glycerin. The product will be available through professional channels and on Obagi.com starting May 5, 2025.
Waldencast (NASDAQ: WALD) reported strong Q4 2024 and full-year financial results. Q4 highlights include net revenue of $72.1 million (29.4% growth), and Adjusted EBITDA of $11.2 million (doubled from Q4 2023). Full-year 2024 delivered net revenue of $273.9 million with 27.5% growth and $40.3 million in Adjusted EBITDA.
Key developments:
- Obagi Medical emerged as the fastest-growing professional skincare brand among top 10 in US for 2024
- Milk Makeup secured expansion to 600+ Ulta Beauty locations for Spring 2025
- Company secured new $205 million credit facility
Brand Performance: Obagi Medical Q4 revenue reached $42.2 million (27.7% growth) with $9.8 million Adjusted EBITDA. Milk Makeup achieved $29.9 million revenue (31.9% growth) with $4.8 million Adjusted EBITDA.
2025 Outlook: Company projects mid-teens revenue growth and Adjusted EBITDA margin expansion into mid-to-high teens, with growth acceleration expected throughout the year.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has scheduled its Fourth Quarter and Fiscal Year 2024 earnings release and conference call. The company will release its financial results on March 18, 2025 after U.S. market close, followed by a conference call with management on March 19, 2025 at 8:30am ET.
Interested investors and analysts can participate by dialing (877) 704-4453, or (201) 389-0920 for international callers. The event will include a slide presentation and will be webcast live at ir.waldencast.com, with the replay remaining available for 90 days.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit on February 26, 2025, in New York. Michel Brousset, Founder and CEO, will engage in a fireside chat presentation at 2:45 p.m. EST and conduct investor meetings throughout the day. The presentation will be available via live webcast and replay on Waldencast's Investor Relations website.
Obagi Medical has announced the launch of two new products in its SUZANOBAGIMD® collection: Super Antioxidant Serum ($158) and Moisture Restore Hydration Replenishing Cream ($78). The products, developed by Chief Medical Director Dr. Suzan Obagi, target skin brightening, oxidative stress, and hydration concerns.
The Super Antioxidant Serum features encapsulated Silymarin and stabilized Vitamin C, while the Moisture Restore cream contains multi-weight Hyaluronic Acids for multi-layered hydration. Clinical testing showed that 94% of subjects experienced refreshed and smoother skin immediately after application, and 97% observed improved overall skin appearance after 2 weeks.
The products will be available through professional channels and on Obagi.com starting February 24, 2025.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its upcoming earnings release and conference call schedule for Q4/FY2024 and the first three quarters of FY2025. Key dates include:
- Q4/FY2024: Earnings release on March 18, 2025, after market close; Conference call on March 19, 2025, at 8:30am ET
- Q1 2025: Earnings release on May 13, 2025, after market close; Conference call on May 14, 2025, at 8:30am ET
- Q2 2025: Earnings release on August 18, 2025, after market close; Conference call on August 19, 2025, at 8:30am ET
- Q3 2025: Earnings release on November 11, 2025, after market close; Conference call on November 12, 2025, at 8:30am ET
All webcasts and presentations will be available on the company's Investor Relations website approximately two weeks before each event.